Mednet Logo

How would you approach a patient with advanced stage DLBCL with a single-site of residual FDG-avid disease after completion of R-CHOP in the frontline setting?

Would you consider this refractory disease and go on to salvage regimen and auto-SCT, or is there a role for definitive XRT to the site of residual disease?
1 Answer
Mednet Member
Mednet Member
Medical Oncology · Rutgers Cancer Institute of New Jersey
Answered on

First would be to assess the residual activity level (e.g. PS 4 or 5), as sometimes a short-interval PET may show improvement. If concern is for residual disease in setting of PET showing partial response, I would consider biopsy of the residual site prior to making any changes in therapy.

Once a d...

Join for free or sign in to see the full answer